Last reviewed · How we verify
Indomethacin Injection
At a glance
| Generic name | Indomethacin Injection |
|---|---|
| Also known as | YINDUOMEIXIN |
| Sponsor | University of Manitoba |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA (PHASE4)
- Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients (PHASE4)
- NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis (PHASE3)
- Optimizing Pain Treatment in Children On Mechanical Ventilation (PHASE3)
- Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy (PHASE3)
- R.E.C.K vs Exparel in Robotic Nephrectomy (PHASE3)
- NSAIDs Stent Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indomethacin Injection CI brief — competitive landscape report
- Indomethacin Injection updates RSS · CI watch RSS
- University of Manitoba portfolio CI